In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
June 23rd, 2008 | 24 | Yes |
Popular Name: 5-[2-(6-methyl-2-pyridyl)-5,6-dihydro-4H-pyrrolo[2,1-e]pyrazol-3-yl]-1H-benzimidazole 5-[2-(6-methyl-2-pyridyl)-5,6-di…
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.71 | 9.23 | -18.03 | 1 | 5 | 0 | 59 | 315.38 | 2 | ↓ |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
TGFR1-1-E | TGF-beta Receptor Type I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 47 | 0.43 | Binding ≤ 10μM |
TGFR2-1-E | TGF-beta Receptor Type II (cluster #1 Of 1), Eukaryotic | Eukaryotes | 1300 | 0.34 | Binding ≤ 10μM |
TGFR1-1-E | TGF-beta Receptor Type I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 42 | 0.43 | Functional ≤ 10μM |
TGFR2-1-E | TGF-beta Receptor Type II (cluster #1 Of 1), Eukaryotic | Eukaryotes | 42 | 0.43 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
TGFR1_HUMAN | P36897 | TGF-beta Receptor Type I, Human | 47 | 0.43 | Binding ≤ 1μM |
TGFR1_HUMAN | P36897 | TGF-beta Receptor Type I, Human | 47 | 0.43 | Binding ≤ 10μM |
TGFR2_HUMAN | P37173 | TGF-beta Receptor Type II, Human | 1300 | 0.34 | Binding ≤ 10μM |
TGFR1_HUMAN | P36897 | TGF-beta Receptor Type I, Human | 15 | 0.46 | Functional ≤ 10μM |
TGFR2_HUMAN | P37173 | TGF-beta Receptor Type II, Human | 42 | 0.43 | Functional ≤ 10μM |
Description | Species |
---|---|
Downregulation of TGF-beta receptor signaling | |
SMAD2/3 MH2 Domain Mutants in Cancer | |
SMAD2/3 Phosphorylation Motif Mutants in Cancer | |
TGF-beta receptor signaling activates SMADs | |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | |
TGFBR1 KD Mutants in Cancer | |
TGFBR1 LBD Mutants in Cancer | |
TGFBR2 Kinase Domain Mutants in Cancer | |
TGFBR2 MSI Frameshift Mutants in Cancer |